1. Home
  2. ITRM vs BLFY Comparison

ITRM vs BLFY Comparison

Compare ITRM & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • BLFY
  • Stock Information
  • Founded
  • ITRM 2015
  • BLFY 1939
  • Country
  • ITRM Ireland
  • BLFY United States
  • Employees
  • ITRM N/A
  • BLFY N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • BLFY Commercial Banks
  • Sector
  • ITRM Health Care
  • BLFY Finance
  • Exchange
  • ITRM Nasdaq
  • BLFY Nasdaq
  • Market Cap
  • ITRM 35.6M
  • BLFY N/A
  • IPO Year
  • ITRM 2018
  • BLFY N/A
  • Fundamental
  • Price
  • ITRM $1.02
  • BLFY $9.98
  • Analyst Decision
  • ITRM Strong Buy
  • BLFY Hold
  • Analyst Count
  • ITRM 2
  • BLFY 2
  • Target Price
  • ITRM $7.00
  • BLFY $11.00
  • AVG Volume (30 Days)
  • ITRM 571.6K
  • BLFY 53.2K
  • Earning Date
  • ITRM 05-13-2025
  • BLFY 04-30-2025
  • Dividend Yield
  • ITRM N/A
  • BLFY N/A
  • EPS Growth
  • ITRM N/A
  • BLFY N/A
  • EPS
  • ITRM N/A
  • BLFY N/A
  • Revenue
  • ITRM N/A
  • BLFY $41,228,000.00
  • Revenue This Year
  • ITRM N/A
  • BLFY $13.64
  • Revenue Next Year
  • ITRM $108.39
  • BLFY $21.23
  • P/E Ratio
  • ITRM N/A
  • BLFY N/A
  • Revenue Growth
  • ITRM N/A
  • BLFY N/A
  • 52 Week Low
  • ITRM $0.81
  • BLFY $8.30
  • 52 Week High
  • ITRM $3.02
  • BLFY $11.48
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 42.76
  • BLFY 67.13
  • Support Level
  • ITRM $0.88
  • BLFY $9.85
  • Resistance Level
  • ITRM $1.14
  • BLFY $10.26
  • Average True Range (ATR)
  • ITRM 0.11
  • BLFY 0.34
  • MACD
  • ITRM -0.01
  • BLFY 0.11
  • Stochastic Oscillator
  • ITRM 25.93
  • BLFY 82.03

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: